Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TPH1 | P17752 | 20/20 | 0.79 |
| ▸ | TPH2 | Q8IWU9 | 11/20 | 0.79 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.65 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.65 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.65 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.65 |
| ▸ | CCKAR | P32238 | 2/20 | 0.65 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.65 |
| ▸ | F2 | P00734 | 1/20 | 0.65 |
| ▸ | ESR1 | P03372 | 1/20 | 0.65 |
| ▸ | DRD1 | P21728 | 1/20 | 0.65 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.65 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.65 |
| ▸ | DRD3 | P35462 | 1/20 | 0.65 |
| ▸ | MLNR | O43193 | 1/20 | 0.56 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.56 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.56 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.56 |
| ▸ | MC3R | P41968 | 1/20 | 0.56 |
| ▸ | HTR3A | P46098 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL610965 | 0.90 | TPH1 (0.85) | TPH1TPH2ADORA3SLC6A2AGTR1 | |
| SCHEMBL610967 | 0.90 | TPH1 (0.85) | TPH1TPH2ADORA3SLC6A2AGTR1 | |
| SCHEMBL610966 | 0.90 | TPH1 (0.85) | TPH1TPH2ADORA3SLC6A2AGTR1 | |
| SCHEMBL869854 | 0.89 | TPH1 (0.63) | TPH1TPH2ADORA3SLC6A2AGTR1 | |
| SCHEMBL27785486 | 0.89 | TPH1 (0.63) | TPH1TPH2ADORA3SLC6A2AGTR1 | |
| SCHEMBL609905 | 0.88 | TPH1 (1.00) | TPH1TPH2ADORA3SLC6A2AGTR1 | |
| SCHEMBL609907 | 0.88 | TPH1 (1.00) | TPH1TPH2ADORA3SLC6A2AGTR1 | |
| SCHEMBL609906 | 0.88 | TPH1 (1.00) | TPH1TPH2ADORA3SLC6A2AGTR1 | |
| SCHEMBL869862 | 0.88 | TPH1 (0.76) | TPH1TPH2ADORA3SLC6A2AGTR1 | |
| SCHEMBL869896 | 0.88 | TPH1 (0.83) | TPH1TPH2ADORA3SLC6A2AGTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3808740-A1 | ORAL DOSAGE FORMS COMPRISING 4-PHENYL-6-(2,2,2-TRIFLUORO-1-PHENYLETHOXY)PYRIMIDINE-BASED COMPOUNDS AND METHODS OF THEIR USE | TerSera Therapeutics LLC (US) | 2021-04-21 | — | — | EP | claimed |
| EP-3176159-A1 | 4-PHENYL-6-(2,2,2-TRIFLUORO-1-PHENYLETHOXY)PYRIMIDINE-BASED COMPOUNDS AND METHODS OF THEIR USE | Lexicon Pharmaceuticals, Inc. (US) | 2017-06-07 | — | — | EP | claimed |
| EP-2589600-A1 | 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use | Lexicon Pharmaceuticals, Inc. (US) | 2013-05-08 | — | — | EP | claimed |
| EP-2091940-A2 | 4-PHENYL-6-(2,2,2-TRIFLUORO-1-PHENYLETHOXY)PYRIMIDINE-BASED COMPOUNDS AND METHODS OF THEIR USE | Lexicon Pharmaceuticals, Inc. (US) | 2009-08-26 | — | — | EP | claimed |
| WO-2008073933-A2 | 4-PHENYL-6-(2,2,2-TRIFLUORO-1-PHENYLETHOXY)PYRIMIDINE-BASED COMPOUNDS AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS, INC. (US) | 2008-06-19 | — | — | WO | claimed |
| EP-3808740-A1 | ORAL DOSAGE FORMS COMPRISING 4-PHENYL-6-(2,2,2-TRIFLUORO-1-PHENYLETHOXY)PYRIMIDINE-BASED COMPOUNDS AND METHODS OF THEIR USE | TerSera Therapeutics LLC (US) | 2021-04-21 | — | — | EP | disclosed |
| EP-3176159-B1 | 4-PHENYL-6-(2,2,2-TRIFLUORO-1-PHENYLETHOXY)PYRIMIDINE-BASED COMPOUNDS AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS INC (US) | 2020-10-21 | — | — | EP | disclosed |
| EP-2091940-B3 | 4-PHENYL-6-(2,2,2-TRIFLUORO-1-PHENYLETHOXY)PYRIMIDINE-BASED COMPOUNDS AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS INC (US) | 2017-12-06 | — | — | EP | disclosed |
| EP-3176159-A1 | 4-PHENYL-6-(2,2,2-TRIFLUORO-1-PHENYLETHOXY)PYRIMIDINE-BASED COMPOUNDS AND METHODS OF THEIR USE | Lexicon Pharmaceuticals, Inc. (US) | 2017-06-07 | — | — | EP | disclosed |
| EP-2589600-B1 | 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use | LEXICON PHARMACEUTICALS INC (US) | 2017-02-15 | — | — | EP | disclosed |
| EP-2091940-B1 | 4-PHENYL-6-(2,2,2-TRIFLUORO-1-PHENYLETHOXY)PYRIMIDINE-BASED COMPOUNDS AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS INC (US) | 2015-12-09 | — | — | EP | disclosed |
| US-9150521-B2 | Methods of preventing and treating diabetes by inhibiting serotonin synthesis | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2015-10-06 | — | — | US | disclosed |
| EP-2589600-A1 | 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use | Lexicon Pharmaceuticals, Inc. (US) | 2013-05-08 | — | — | EP | disclosed |
| WO-2012058598-A1 | METHODS OF PREVENTING AND TREATING HYPERLIPIDEMIA OR ATHEROSCLEROSIS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2012-05-03 | — | — | WO | disclosed |
| WO-2012054388-A1 | TPH1 INHIBITORS AND BISPHOSPHONATES FOR PREVENTING AND TREATING LOW BONE MASS DISEASES | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2012-04-26 | — | — | WO | disclosed |
| US-20120077831-A1 | METHODS AND ASSAYS FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME | LEXICON PHARMACEUTICALS, INC. | 2012-03-29 | — | — | US | disclosed |
| US-20110281899-A1 | METHODS OF PREVENTING AND TREATING LOW BONE MASS DISEASES | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2011-11-17 | — | — | US | disclosed |
| US-20110124667-A1 | METHODS FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME | LEXICON PHARMACEUTICALS, INC. | 2011-05-26 | — | — | US | disclosed |
| WO-2011063181-A1 | METHODS AND ASSAYS FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME | LEXICON PHARMACEUTICALS, INC. (US) | 2011-05-26 | — | — | WO | disclosed |
| WO-2010056992-A1 | METHODS OF PREVENTING AND TREATING LOW BONE MASS DISEASES | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2010-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077831-A1 | METHODS AND ASSAYS FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME | SI, HNMT, ALPI | TPH1 65/4885TPH2 50/4885ADORA3 745/4885 |
| US-20110281899-A1 | METHODS OF PREVENTING AND TREATING LOW BONE MASS DISEASES | TPH1, HTR1A, TPH2 | TPH1 1/4885TPH2 3/4885ADORA3 47/4885 |
| US-20110124667-A1 | METHODS FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME | SI, HNMT, SLC10A2 | TPH1 85/4885TPH2 63/4885ADORA3 591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.